# Grok-4.1-Fast Review

**Role:** External referee review
**Model:** x-ai/grok-4.1-fast
**Paper:** paper.pdf
**Timestamp:** 2026-02-27T00:38:27.252921
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 17348 in / 2979 out
**Response SHA256:** 0e35f80be4bc7657

---

## 1. IDENTIFICATION AND EMPIRICAL DESIGN (CRITICAL)

The identification strategy is credible and progressively strengthens for diagnosing "cosmopolitan confounding" in SCI-based shift-share designs. The baseline continuous-treatment DiD (Eq. 2, Table 1, p. 14) credibly reveals the problem: German SCI yields a larger coeff (0.043, p=0.01) than UK SCI (0.025, p=0.03), despite no German shock (Sec. 2, p. 8). Key assumptions (parallel trends, no anticipation) are explicit and tested via event studies (Figs. 3-4, pp. 18-19): baseline pre-trends borderline violate (joint F p=0.038-0.048 for DiD; p=0.240 for triple-diff gap, validating the latter). Treatment timing coherent: post=1 from 2016Q3 (referendum), data 2014-2023 no gaps (Table 1 summary stats, p. 13; N=3510 dept-qtr).

Threats addressed innovatively:
- **Post-treatment SCI bias**: Pre-2016 census stock (Jan 1, 2016 ref date, Sec. 4.2, p. 12) yields robust coeff (0.011, p=0.002, Table 1 col2).
- **Omitted confounders**: Residualized SCI (orthogonal to DE/CH SCI, coastal, etc., Sec. 2.2, p. 9; Table 1 col3 insignificant).
- **Unit-time shocks**: Triple-diff (Eq. 3, Sec. 3.2, p. 11; Table 2, p. 17) exploits British preference for houses (maisons) vs apartments, absorbing *all* dept×qtr shocks via φ_dt FE. German placebo null (0.008, p=0.67; Table 2 col4; p>0.6 full sample), confirming design diagnostic success. GADM1-harmonized battery (Sec. 3.4/Sec. 5.3, Table 5 p. 21) ensures symmetric resolution.
- **Placebos/falsification**: Multi-country battery (Tables 5-6, pp. 21-22); epoch decomp (Sec. 6, Table 4 p. 24) disentangles Brexit (2016Q3-2019Q4: δ=0) vs COVID (2020+: δ=0.055 SCI p=0.01).

Minor issues: Triple-diff assumes symmetric house-apartment shocks absent UK demand (Sec. 9.2, p. 37); COVID controls (Table 7 p. 26) reassuring but not definitive. No RDD, staggered DiD, or continuity assumptions. Overall, strategy shifts from naive to highly credible, with diagnostics central to causal claims on confounding (not full Brexit causality).

## 2. INFERENCE AND STATISTICAL VALIDITY (CRITICAL)

Inference valid and transparent; paper passes this critical bar.

- **SE/uncertainty**: Dept-clustered SE throughout (96 clusters, adequate; e.g., Table 1). CIs in event studies/figs (Figs. 3-5,8,10,12). P-values appropriate; bootstrap pairs (499 reps, Table 9 p. 28; Fig. 12?) confirms (e.g., SCI triple-diff p=0.054 bootstrap vs 0.106 cluster-robust).
- **Sample sizes**: Explicit/coherent (e.g., Table 1: 3510 dept-qtr; 7010/6412 property-type after singletons; notes detail). Commune-level (Table 13 p. 32, N~215k) tighter SE.
- **No TWFE violation**: Not staggered (uniform post-2016Q3).
- **Event studies**: Pre-trend F-tests reported (Figs. 4-5, p.19; honestDiD Fig. 11 p.31).
- **Placebos**: Bonferroni for 5-tests noted (Table 5 note, p.21).
- **Permutation/LOO**: Figs. 13-14 (pp. 34-35).

No major flaws; bootstrap addresses small-cluster concern. Within R² low but expected (saturated FEs, e.g., triple-diff 0.001, note Table 2).

## 3. ROBUSTNESS AND ALTERNATIVE EXPLANATIONS

Extensive and meaningful:
- **Specs**: Controls (Table 1 col4), trends (Table 1 col6 null, expected saturation), short sample (2014-18: 0.007 p=0.008 Table 14 col4 p.33), binary Q5 (imprecise), no IdF/Corsica (stable).
- **Placebos**: German null in triple-diff; GADM1 battery (UK strongest DiD); horse-race attenuates others.
- **Mechanisms**: Distinguished (Sec. 8): XR channel (Table 10 p.35, negative as expected but German also sig.); geo-het (Table 11 p.36); COVID controls (Table 7 p.26).
- **Epoch**: Cleanly shows COVID timing (Table 4; Brexit δ~0).
- **Alt levels**: Commune triple-diff (Table 13 p.32, stock p=0.09).
- **Sensitivity**: HonestDiD (Fig.11), permutation/LOO (Figs.13-14).

Limitations stated (Sec. 9.2-3, pp.36-37): no buyer nat'lty, potential type-specific shocks, GADM1 multicollinearity/power. Falsification strong (null German), but some GADM1 placebos sig (Italy post-Bonferroni).

## 4. CONTRIBUTION AND LITERATURE POSITIONING

Clear methodological contribution: First systematic SCI confounding diagnosis (cosmopolitan bias akin to shift-share, cites Borusyak/Goldsmith-Pinkham/Adao appropriately, Sec. 2.1 p.8). Toolkit (census, residualize, triple-diff, harmonized placebos) replicable (GitHub). Differs from prior SCI (Bailey et al. 2018-21; Sable-Greenberg 2023) by exposing flaw via Brexit lab.

Lit coverage sufficient: SCI methods (core cites); Brexit econ (Born 2019, Breinlich 2019/22, Hassan 2024, Bloom 2025); housing foreign demand (Badarinza 2019, Favara 2015). Policy domain (housing/immigration) covered. No major omissions; add de Chaisemartin/D'Haultfoeuille 2020 on DiD pre-trends (event study borderline) and Autor et al. 2020 shift-share for network analogy.

## 5. RESULTS INTERPRETATION AND CLAIM CALIBRATION

Well-calibrated overall, honest on limits (Sec. 9.2: "does *not* establish clean Brexit attribution"; estimand as "post-2020 house gap"). Effects small (e.g., 1SD stock ~0.4pp house gap, "modest" p.17) match uncertainty (triple-diff p~0.1-0.6). Policy proportional: SCI diagnostics, not Brexit policy rx.

Flags:
- Overclaim subtle: Intro/Sec.1 claims "UK-connected depts experienced differential house-appreciation after 2016" (p.2), but epoch shows Brexit=0, full-sample driven by COVID.
- Inconsistent: Baseline DiD stock robust (p=0.002), triple-diff weak (p=0.57); text emphasizes former less (Sec.5.2 p.17).
- Tables support claims (e.g., German > UK baseline; null triple-placebo), but GADM1 triple has Italy sig (not over-interpreted).

## 6. ACTIONABLE REVISION REQUESTS

### 1. Must-fix issues before acceptance
1. **Clarify/resolve triple-diff insignificance vs baseline robustness**: Issue: Tightest spec (Table 2) has δ=0.029 SCI (p=0.106), 0.003 stock (p=0.57); bootstrap helps SCI (p=0.054) but not stock. Why prioritize insignificant tight spec? Matters for credibility—readers may dismiss as null. Fix: Add power calcs (e.g., min detectable effect); report weighted epoch avg matching full-sample (already noted p.24, expand); horse-race all exposures in triple-diff.
2. **Tone causal claims to timing evidence**: Issue: Abstract/Intro imply Brexit causal (e.g., "Brexit as laboratory", p.1); Sec.9.2 corrects but inconsistent. Matters: Misleads on Brexit vs COVID. Fix: Rewrite abstract/intro/concl to lead with "diagnoses SCI confound using Brexit lab; detects post-2020 UK-specific house signal consistent with network-amplified sorting".
3. **GADM1 placebos**: Issue: Triple-diff sig for BE/IT/ES individually (Table 5); Italy survives Bonferroni/horse-race. Matters: Undermines "UK-only" claim. Fix: Test if driven by specific regions (e.g., Provence IT); report family-wise error.

### 2. High-value improvements
1. **Pre-trend violation**: Issue: Baseline event joint p~0.04 (Fig.3); honestDiD shows sensitivity (Fig.11). Matters: Weakens DiD. Fix: Lead with triple-diff gap validation (p=0.24); apply honestDiD to triple-diff.
2. **Direct mechanism test**: Issue: No buyer data; house pref anecdotal (p.11). Matters: Core assumption. Fix: Tabulate house/apartment shares by UK stock quintiles; cite/search notarial stats.
3. **Add shift-share refs**: Issue: Analogous to Bartik (missing de Chaisemartin 2024 multi-period). Matters: Positions better. Fix: Cite/discuss in Sec.2.1.

### 3. Optional polish
1. **XR channel**: German placebo sig (Table 10); discuss macro corr.
2. **Commune SCI construction**: Detail aggregation (Table 13).
3. **Effect size calibration**: Compare to total Brexit housing lit magnitudes.

## 7. OVERALL ASSESSMENT

**Key strengths**: Novel, replicable SCI diagnostic toolkit with clean lab (Brexit cross-border); rigorous progression (baseline confound → fixes → diagnostics); extensive robustness (bootstrap, epochs, multi-placebo); honest limits/timing.

**Critical weaknesses**: Triple-diff imprecise (p>0.1, small effects); timing confounds Brexit claim (post-2020 only); some residual placebos (GADM1); borderline baseline pre-trends.

**Publishability after revision**: High potential for AEJ:Methods or top general (methods + app); salvageable with claim recalibration, power/SE emphasis, mechanism bolstering.

DECISION: MAJOR REVISION